Trial Profile
Study of Carfilzomib in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Oct 2020 Status changed from active, no longer recruiting to completed.
- 17 Jun 2018 Preliminary results (data cut off: 31 Dec, 2017; n=30) presented at the 23rd Congress of the European Haematology Association.
- 17 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2020.